MX2021000089A - Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn). - Google Patents
Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn).Info
- Publication number
- MX2021000089A MX2021000089A MX2021000089A MX2021000089A MX2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- group
- sup
- virus infection
- rna virus
- Prior art date
Links
- 208000009341 RNA Virus Infections Diseases 0.000 title abstract 3
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de la fórmula (I) o cualquiera de sus sales farmacéuticamente aceptables para usarse en el tratamiento y/o prevención de una infección por virus de ARN, y en particular una infección por virus de ARN del grupo IV o V de la clasificación de Baltimore. (ver Fórmula) en donde R3 representa un átomo de cloro o un átomo de hidrógeno, R representa un grupo alquilo (C1-C4), un grupo cicloalquilo (C3-C6), un átomo de halógeno, un grupo alcoxi (C1-C5), un grupo -SO2-NRaRb, un grupo -SO3H, un grupo -OH, un grupo -O-SO2-ORc o un grupo -OP(=O) (ORc)(ORd), R1 representa (i) un grupo CF3, (ii) un alquilo (C1-C10) grupo, (iii) un cicloalquilo (C3-C6) o un grupo heterocicloalquilo (C3-C6) o (iv) un grupo fenilo o un grupo naftilo, y R2 representa un átomo de hidrógeno, un grupo alquilo (C1-C10), un grupo cicloalquilo (C3-C6) o heterocicloalquilo (C3-C6). La presente invención se refiere además a nuevos compuestos, a composiciones farmacéuticas que los contienen y al proceso de síntesis para manufacturarlos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305910.4A EP3594206A1 (en) | 2018-07-09 | 2018-07-09 | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| PCT/EP2019/068459 WO2020011810A1 (en) | 2018-07-09 | 2019-07-09 | Phenyl-n-quinoline derivatives for treating a rna virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000089A true MX2021000089A (es) | 2021-03-25 |
Family
ID=63035966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000089A MX2021000089A (es) | 2018-07-09 | 2019-07-09 | Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12084422B2 (es) |
| EP (2) | EP3594206A1 (es) |
| JP (2) | JP7504409B2 (es) |
| KR (1) | KR102758510B1 (es) |
| CN (1) | CN112566899B (es) |
| AU (1) | AU2019300100B2 (es) |
| BR (1) | BR112021000331A2 (es) |
| CA (1) | CA3103867A1 (es) |
| CU (1) | CU24674B1 (es) |
| MX (1) | MX2021000089A (es) |
| WO (1) | WO2020011810A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3172179A1 (en) | 2020-03-20 | 2021-09-23 | Jamal Tazi | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| WO2025045123A1 (zh) * | 2023-08-30 | 2025-03-06 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| FR2830862A1 (fr) | 2001-10-16 | 2003-04-18 | Lipha | Derives nitroso de la diphenylamine a fonction ether ou thioether, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| BRPI0413740A (pt) | 2003-08-21 | 2006-10-24 | Osi Pharm Inc | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| EP1697343B1 (en) | 2003-12-18 | 2009-07-01 | Tibotec Pharmaceuticals Ltd. | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| FR2866647B1 (fr) * | 2004-02-20 | 2006-10-27 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2006037117A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| BRPI0606278B8 (pt) | 2005-03-17 | 2021-05-25 | Janssen R & D Ireland | aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica |
| US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
| DE602006015861D1 (de) | 2005-12-21 | 2010-09-09 | Abbott Lab | Antivirale verbindungen |
| FR2901273B1 (fr) | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| US20140187641A1 (en) | 2012-08-23 | 2014-07-03 | Gtx | Estrogen receptor ligands and methods of use thereof |
| EP4198022A1 (en) | 2009-06-12 | 2023-06-21 | Abivax | Preparation of compounds useful for treating aids |
| JP2011026251A (ja) | 2009-07-27 | 2011-02-10 | Kowa Co | ２−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
| SG186341A1 (en) | 2010-06-24 | 2013-01-30 | Takeda Pharmaceutical | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2505198A1 (en) | 2011-04-01 | 2012-10-03 | Société Splicos | Compounds for use as therapeutic agents affecting p53 expression and/or activity |
| WO2014164667A1 (en) | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| WO2015001518A1 (en) * | 2013-07-05 | 2015-01-08 | Splicos | Bicyclic compounds useful for treating diseases caused by retroviruses |
| RU2628800C2 (ru) | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
-
2018
- 2018-07-09 EP EP18305910.4A patent/EP3594206A1/en not_active Ceased
-
2019
- 2019-07-09 BR BR112021000331-2A patent/BR112021000331A2/pt unknown
- 2019-07-09 MX MX2021000089A patent/MX2021000089A/es unknown
- 2019-07-09 JP JP2021500215A patent/JP7504409B2/ja active Active
- 2019-07-09 AU AU2019300100A patent/AU2019300100B2/en active Active
- 2019-07-09 US US17/259,364 patent/US12084422B2/en active Active
- 2019-07-09 KR KR1020217001298A patent/KR102758510B1/ko active Active
- 2019-07-09 WO PCT/EP2019/068459 patent/WO2020011810A1/en active Application Filing
- 2019-07-09 CU CU2021000006A patent/CU24674B1/es unknown
- 2019-07-09 EP EP19737536.3A patent/EP3820852A1/en active Pending
- 2019-07-09 CN CN201980045917.4A patent/CN112566899B/zh active Active
- 2019-07-09 CA CA3103867A patent/CA3103867A1/en active Pending
-
2023
- 2023-10-17 JP JP2023179000A patent/JP7673362B2/ja active Active
-
2024
- 2024-05-10 US US18/660,578 patent/US20240308964A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3594206A1 (en) | 2020-01-15 |
| WO2020011810A1 (en) | 2020-01-16 |
| KR102758510B1 (ko) | 2025-01-22 |
| CN112566899B (zh) | 2024-01-30 |
| CA3103867A1 (en) | 2020-01-16 |
| CU20210006A7 (es) | 2021-08-06 |
| JP2021524481A (ja) | 2021-09-13 |
| US20210309611A1 (en) | 2021-10-07 |
| JP2024053563A (ja) | 2024-04-15 |
| US12084422B2 (en) | 2024-09-10 |
| CN112566899A (zh) | 2021-03-26 |
| AU2019300100B2 (en) | 2024-10-24 |
| AU2019300100A1 (en) | 2021-01-21 |
| JP7504409B2 (ja) | 2024-06-24 |
| US20240308964A1 (en) | 2024-09-19 |
| KR20210052432A (ko) | 2021-05-10 |
| JP7673362B2 (ja) | 2025-05-09 |
| BR112021000331A2 (pt) | 2021-04-06 |
| EP3820852A1 (en) | 2021-05-19 |
| CU24674B1 (es) | 2023-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000089A (es) | Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn). | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| MX2017002241A (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| MX2020011294A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina. | |
| TW200745066A (en) | Novel PTP1B inhibitors | |
| CY1113099T1 (el) | Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2 | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| NO20061793L (no) | 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| TW200833675A (en) | Nicotinamide derivatives | |
| IL204594A (en) | Protein kinase inhibitors | |
| NO20081582L (no) | Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer | |
| NO20065327L (no) | Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid. | |
| CY1111980T1 (el) | Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης | |
| NZ601967A (en) | Pde10 inhibitors and related compositions and methods | |
| MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| MX2021000095A (es) | Derivados de aril-n-arilo para el tratamiento de una infeccion por virus de acido ribonucleico (arn). | |
| EP4001276A1 (en) | Aurora kinase inhibitor and use thereof | |
| MA40480B1 (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| ATE413876T1 (de) | Indolamid-derivate, die glycogen phosphorylase inhibierende aktivität besitzen | |
| EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
| ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen |